scholarly journals Evidence That FoxP3+ Regulatory T Cells May Play a Role in Promoting Long-Term Acceptance of Composite Tissue Allotransplants

2011 ◽  
Vol 91 (8) ◽  
pp. 908-915 ◽  
Author(s):  
Larry D. Bozulic ◽  
Yujie Wen ◽  
Hong Xu ◽  
Suzanne T. Ildstad
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Composite Tissue

Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis

2021 ◽  
pp. 135245852110033
Author(s):  
Quentin Howlett-Prieto ◽  
Xuan Feng ◽  
John F Kramer ◽  
Kevin J Kramer ◽  
Timothy W Houston ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Regulatory T Cells ◽  
B Cell ◽  
Regulatory T Cell ◽  
Healthy Controls ◽  
Regulatory Cells ◽  
Long Term Treatment ◽  
Anti Cd20

Objective: To determine the effect of long-term anti-CD20 B-cell-depleting treatment on regulatory T cell immune subsets that are subnormal in untreated MS patients. Methods: 30 clinically stable MS patients, before and over 38 months of ocrelizumab treatment, were compared to 13 healthy controls, 29 therapy-naïve MS, 9 interferon-β-treated MS, 3 rituximab-treated MS, and 3 rituximab-treated patients with other autoimmune inflammatory diseases. CD8, CD28, CD4, and FOXP3 expression in peripheral blood mononuclear cells was quantitated with flow cytometry. Results: CD8+ CD28− regulatory cells rose from one-third of healthy control levels before ocrelizumab treatment (2.68% vs 7.98%), normalized by 12 months (13.5%), and rose to 2.4-fold above healthy controls after 18 months of ocrelizumab therapy (19.0%). CD4+ FOXP3+ regulatory cells were lower in MS than in healthy controls (7.98%) and showed slight long-term decreases with ocrelizumab. CD8+ CD28− and CD4+ FOXP3+ regulatory T cell percentages in IFN-β-treated MS patients were between those of untreated MS and healthy controls. Interpretation: Long-term treatment with ocrelizumab markedly enriches CD8+ CD28− regulatory T cells and corrects the low levels seen in MS before treatment, while slightly decreasing CD4+ FOXP3+ regulatory T cells. Homeostatic enrichment of regulatory CD8 T cells provides a mechanism, in addition to B cell depletion, for the benefits of anti-CD20 treatment in MS.

Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis

2010 ◽  
Vol 38 (8) ◽  
pp. 1718-1725 ◽  
Author(s):  
Daniele C. Nascimento ◽  
José C. Alves-Filho ◽  
Fabiane Sônego ◽  
Sandra Y. Fukada ◽  
Marcelo S. Pereira ◽  
...  
Keyword(s):  
T Cells ◽  
Severe Sepsis ◽  
Regulatory T Cells ◽  
Immune Dysfunction

CD25 regulatory T cells determine secondary but not primary remission in EAE: Impact on long-term disease progression☆

2006 ◽  
Vol 172 (1-2) ◽  
pp. 73-84 ◽  
Author(s):  
D GARTNER ◽  
H HOFF ◽  
U GIMSA ◽  
G BURMESTER ◽  
M BRUNNERWEINZIERL
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Disease Progression

scholarly journals Regulatory T Cells and Kidney Transplantation

2018 ◽  
Vol 13 (11) ◽  
pp. 1760-1764 ◽  
Author(s):  
Paloma Leticia Martin-Moreno ◽  
Sudipta Tripathi ◽  
Anil Chandraker
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Organ Transplantation ◽  
Tissue Repair ◽  
Solid Organ Transplantation ◽  
Immunosuppressive Drugs ◽  
Solid Organ ◽  
Effective Expansion ◽  
Conventional Immunosuppression

The ability of the immune system to differentiate self from nonself is critical in determining the immune response to antigens expressed on transplanted tissue. Even with conventional immunosuppression, acceptance of the allograft is an active process often determined by the presence of regulatory T cells (Tregs). Tregs classically are CD4+ cells that constitutively express high levels of the IL-2 receptor α chain CD25, along with the transcription factor Foxp3. The use of Tregs in the field of solid organ transplantation is related specifically to the objective of achieving tolerance, with the goal of reducing or eliminating immunosuppressive drugs as well as maintaining tissue repair and managing acute rejection. A key issue in clinical use of Tregs is how to effectively expand the number of Tregs, either through increasing numbers of endogenous Tregs or by the direct infusion of exogenously expanded Tregs. In order to realize the benefits of Treg therapy in solid organ transplantation, a number of outstanding challenges need to be overcome, including assuring an effective expansion of Tregs, improving long-term Treg stability and reduction of risk-related to off-target, nonspecific, immunosuppressive effects related specially to cancer.

Long-term tolerance towards vascularized composite allograft transplantation is due to naturally derived regulatory T-cells

2012 ◽  
Vol 215 (3) ◽  
pp. S90-S91
Author(s):  
Jeff Chang ◽  
Billana Hwang ◽  
Tiffany Butts ◽  
Scott S. Graves ◽  
Rainer Storb ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Allograft Transplantation ◽  
Vascularized Composite Allograft

scholarly journals PRESENCE OF GRAFT-INFILTRATING REGULATORY T CELLS ARE ASSOCIATED WITH LONG TERM CARDIAC XENOGRAFT SURVIVAL IN NON-HUMAN PRIMATE

2020 ◽  
Vol 104 (S3) ◽  
pp. S641-S641
Author(s):  
Avneesh Singh ◽  
Corbin E. Goerlich ◽  
Gheorghe Braileanu ◽  
Alena Hershfeld ◽  
Tianshu Zhang ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Human Primate

Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α

Blood ◽  
2011 ◽  
Vol 118 (8) ◽  
pp. 2170-2173 ◽  
Author(s):  
Caroline Hasselbalch Riley ◽  
Morten Krogh Jensen ◽  
Marie Klinge Brimnes ◽  
Hans Carl Hasselbalch ◽  
Ole Weis Bjerrum ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Myeloproliferative Neoplasms ◽  
Term Treatment ◽  
Immune Reactivity ◽  
Chronic Myeloproliferative Neoplasms ◽  
Healthy Donors ◽  
Long Term Treatment ◽  
And Function

Abstract Recent reports have described complete or major molecular remission in patients with polycythemia vera after long-term treatment with the immunomodulatory agent IFN-α2. Accordingly, there are reasons to believe that the immune system is a key player in eradicating the JAK2 mutated clone in these patients. Foxp3+ regulatory T cells play a pivotal role in maintaining immune homeostasis and, importantly, preventing immune reactivity to self-antigens; however, their suppressive activity can compromise an effective antitumor immune response, and high frequencies of regulatory T cells in peripheral blood have been reported in both hematologic and solid cancers. We have analyzed the number, phenotype, and function of circulating CD4+CD25+Foxp3+ T cells in patients with chronic myeloproliferative neoplasms. Surprisingly, we found a marked expansion of this subset of lymphocytes in patients treated with IFN-α2 (13.0%; 95% confidence interval [CI] 10.8% to 15.2%) compared with healthy donors (6.1%; 95% CI 4.9% to 7.2%), patients with untreated chronic myeloproliferative neoplasms (6.9%; 95% CI 5.8% to 7.4%), or patients treated with hydroxyurea (5.8%; 95% CI 4.3% to 7.4%; P < .0001).

Sign in / Sign up

Export Citation Format

Share Document